Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.
about
[Medication treatment of rheumatoid arthritis with a history of malignancy. Epidemiological data].Malignancy in systemic lupus erythematosus: what have we learned?Systemic lupus erythematosus: review of synthetic drugs.Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis.Genomic expression profiling and bioinformatics analysis of pancreatic cancerCancer risk in systemic lupus: an updated international multi-centre cohort study.Lupus: improving long-term prognosis.Malignancies in systemic lupus erythematosusSLE and Non-Hodgkin's Lymphoma: A Case Series and Review of the LiteratureAvoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis.Squamous cell carcinoma on the palate in a patient with systemic lupus erythematosus: case report and review of literature.The role of antimalarial agents in the treatment of SLE and lupus nephritis.Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.Breast cancer in systemic lupus.[Safety of immunosuppressants].Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.Hydroxychloroquine: the cornerstone of lupus therapy.Effects of chronic exposure of hydroxychloroquine/chloroquine on the risk of cancer, metastasis, and death: a population-based cohort study on patients with connective tissue diseases.
P2860
Q31036951-94546DC4-A4F0-4C2A-BA1A-F590098ACA00Q34087859-FEC9A58C-58D4-43AA-90F1-F75B12880A8EQ34498515-54F79F88-021E-4362-8725-51468BF3B45EQ35006892-8E48F7E5-7950-4284-9E1F-B9E90DCDF0D4Q35919898-1A88B63F-21FF-42F6-AE7A-63E19AAE1CA1Q36823763-292A4FA7-D5C7-4978-917E-38B356193909Q37121353-4CA24C4C-5C7E-4181-A6AE-95FAE297F214Q37433350-763739AA-33A2-4233-80C6-D3EFC6C6AC37Q37744056-5F799AD8-381F-40E8-B502-C58C6FEF1010Q37763904-DE099467-91E8-4138-917A-74A94D97B486Q37819551-D3958C34-0560-4F52-8073-66AE166B751EQ37947108-035C434C-132C-4622-AFE9-A6D6B84D0CC3Q38029146-9FFFE4BF-5DDB-41F4-9301-5D10C38979B4Q40559886-6A9D9F30-EDBE-4BAC-94AD-101BC0DA77C1Q41929021-22768428-5831-4AD8-BD5E-A88AADD1E1FFQ41941085-BA98F0B3-218C-40AC-A265-D10B60CBF33FQ46643929-D72AC2BE-3AFB-4EF3-AAD4-3DCD50A727FFQ47138361-FDB5FBF0-C948-43A1-8A7A-2CC325DE92A9
P2860
Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.
@ast
Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.
@en
type
label
Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.
@ast
Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.
@en
prefLabel
Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.
@ast
Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.
@en
P2093
P2860
P356
P1476
Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.
@en
P2093
A Martinez-Berriotxoa
J I Pijoan
M Garmendia
M V Egurbide
P2860
P304
P356
10.1136/ARD.2006.067777
P407
P577
2007-01-04T00:00:00Z